BMY Bristol-Myers Squibb Company

$0.16 (0.27%)

BMY Stock Analysis Overview

What this means: Bristol-Myers Squibb Company (BMY) gets an Overall Rank of 71, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. BMY's 71 means that it ranks higher than 71% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full BMY report

Bristol-Myers Squibb Company (BMY) Analyst Forecast

Next 12 months ➝Current Price$59.1452-week High$68.3452-week Low$42.48MEAN$65.78+11.22%HIGH$80.00+35.27%LOW$50.00-15.45%
  • Last Price$59.14
  • Previous Close$58.98
  • Change $0.16
  • Open$59.30
  • Volume11,366,050
  • Avg. Volume (100-day)16,611,955
  • Market Capitalization$134B
  • Days Range $58.75 - $59.64
  • 52-week Range $42.48 - $68.34
  • Dividend Yield3.04%
  • Ex. Dividend Date07/02/2020
  • P-E95.4
  • EPS0.62
  • Earnings Date08/06/2020
  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • Avg. Analyst Rec.
  • Beta0.754
  • PEG Ratio1.14
  • Volatility0.27
  • Average True Range0.02
Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.